

# ESMO 2021 Industry Satellite Symposium

## Discussion on Emerging Agents in Breast Cancer Care

Tuesday, 21 September 2021, 17:35–19:05 CEST, Channel 4

### An expert panel of speakers will

- Review the evolution of the breast cancer treatment landscape and current standard of care therapies, with a focus on the metastatic setting
- Discuss existing gaps in the HER2-positive, HR-positive and triple-negative breast cancer treatment pathways
- Evaluate the role of emerging investigational agents, including their mechanism of action, efficacy and tolerability



17:35–17:40 CEST

#### Welcome and introductions

**Dr David Miles (Chair)**, Mount Vernon Cancer Centre, U.K.



17:40–18:00 CEST

#### A new era of next generation therapies in HER2-positive breast cancer

**Dr Mark Pegram**, Stanford University School of Medicine, U.S.



18:00–18:20 CEST

#### Breakthrough developments in triple-negative breast cancer

**Prof Seock-Ah Im**, Seoul National University College of Medicine, South Korea



18:20–18:40 CEST

#### HR-positive breast cancer: emerging trends in cancer treatment

**Dr Erika Hamilton**, Sarah Cannon Research Institute, Tennessee Oncology, U.S.



18:40–19:00 CEST

#### Panel discussion and live Q&A

Involving all faculty: **Dr David Miles (Chair)**, **Dr Mark Pegram**, **Dr Erika Hamilton** and **Prof Seock-Ah Im**



19:00–19:05 CEST

#### Summary and close

**Dr David Miles (Chair)**, Mount Vernon Cancer Centre, U.K.